Thalassemia Major Clinical Trial
Official title:
Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma
Verified date | January 7, 2016 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Thalassemia major (TM) is a chronic disorder that affects a person s ability to produce
hemoglobin, resulting in anemia. Hemoglobin is a component of red blood cells that
carries oxygen and nutrients to cells in the body. As a result, individuals require
life-long blood transfusions and extensive medical management. Studies have shown that
because of its demanding nature, TM might negatively affect an individual s quality of
life, sense of self, and social integration, but little is known about affected
individuals overall experiences with and perceptions of TM.
- TM is caused by a genetic change in the thalassemia gene. The disease is passed to
children by parents who carry one copy of the altered thalassemia gene. The parents are
called carriers of the condition and have a 25 percent chance of having a child with TM.
It is possible to screen for carriers of TM and use this information for pregnancy
planning and management.
- TM is common among people from South and South East Asia and is an important public
health concern in Singapore. More research is needed to explore the lives of people with
TM, and the societal perceptions that exist in Singapore about TM.
Objectives:
- To describe the familial, social, and professional experiences of individuals with TM.
- To investigate the social messages being given out about TM in Singapore and the sources
of those messages.
- To explore the impact of these experiences, perceptions, and social messages on
individuals who have TM.
- To explore how the experiences and perceptions of individuals who have TM affect their
life, sense of self, social integration, and compliance with medical treatment.
Eligibility:
- Residents of Singapore who are 14 years of age or older, can speak English, and
currently have TM.
- Parents of individuals with TM who are 14 years of age or older. Parents must be 21
years of age or older, be able to speak English, and have had caregiving
responsibilities for their child at some point.
Design:
- All participants will have a one-time semi-structured interview, followed by a
questionnaire to obtain demographic information.
- Interviews will be conducted in Singapore and are expected to last for 30 to 90 minutes.
- Individuals with TM will be asked about their own perceptions of TM; familial, social,
and professional experiences involving TM; and their perceptions of others views and of
social messages related to TM.
- Parents of individuals with TM will be asked about their experiences in caring for a
child with TM, talking to their child about TM, telling people about their child s TM,
and interacting with health care providers.
Status | Completed |
Enrollment | 30 |
Est. completion date | January 7, 2016 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years and older |
Eligibility |
- INCLUSION CRITERIA: - Individuals who currently have TM and receive at least 8 blood transfusions in a year - Residents of Singapore - Must speak English - Parents of individuals with TM will be eligible for participation if they are age 21 years or older - Parents must be residents of Singapore - Parents must speak English - For a parent to participate in the study, it will not be required that his or her child also participate in the study or vice versa. EXCLUSION CRITERIA: - Children under age 14 years - Non-English speaking individuals |
Country | Name | City | State |
---|---|---|---|
Singapore | KK Women's & Children's Hospital | Singapore | |
Singapore | Singapore General Hospital Outram Rd. | Singapore |
Lead Sponsor | Collaborator |
---|---|
National Human Genome Research Institute (NHGRI) |
Singapore,
Hoedemaekers R, ten Have H. Geneticization: the Cyprus paradigm. J Med Philos. 1998 Jun;23(3):274-87. — View Citation
Ismail A, Campbell MJ, Ibrahim HM, Jones GL. Health Related Quality of Life in Malaysian children with thalassaemia. Health Qual Life Outcomes. 2006 Jul 2;4:39. — View Citation
Major B, O'Brien LT. The social psychology of stigma. Annu Rev Psychol. 2005;56:393-421. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02559648 -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
|
Phase 2 | |
Recruiting |
NCT02126046 -
Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major
|
N/A | |
Completed |
NCT01125254 -
Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
|
Phase 2/Phase 3 | |
Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
Completed |
NCT00733811 -
Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
|
Phase 4 | |
Enrolling by invitation |
NCT02986698 -
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
|
Phase 1 | |
Not yet recruiting |
NCT06026839 -
Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
|
||
Terminated |
NCT00007072 -
Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major
|
Phase 2 | |
Completed |
NCT04292314 -
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
|
Phase 2/Phase 3 | |
Completed |
NCT02049450 -
Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
|
Phase 2 | |
Active, not recruiting |
NCT04523376 -
Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies
|
N/A | |
Completed |
NCT03992001 -
Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients
|
Phase 4 | |
Not yet recruiting |
NCT05777733 -
NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
|
Phase 1 | |
Completed |
NCT01241357 -
High-Tc Susceptometer to Monitor Transfusional Iron Overload
|
Phase 2 | |
Completed |
NCT00749515 -
Pilot Study for Patients With Poor Response to Deferasirox
|
Phase 4 | |
Completed |
NCT04260516 -
The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major
|
Phase 1 | |
Recruiting |
NCT02307786 -
Long Term Outcomes in β Thalassemia Major
|
N/A | |
Not yet recruiting |
NCT01323608 -
The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
|
Phase 4 | |
Completed |
NCT00005893 -
Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders
|
N/A | |
Recruiting |
NCT06137079 -
"Iron Overload and Endocrinological Diseases"
|